{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=9", "query": { "condition": "Advanced/Metastatic", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 3813, "total_pages": 382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T04:02:50.677Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02584634", "title": "Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "PF-06463922", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-12-18", "completion_date": "2022-07-13", "has_results": true, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584634" }, { "nct_id": "NCT04983407", "title": "Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "batiraxcept", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aravive, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-07-28", "completion_date": "2023-08-14", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 17, "location_summary": "Santa Monica, California • Boca Raton, Florida • Tampa, Florida + 12 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04983407" }, { "nct_id": "NCT03311334", "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Urothelial Carcinoma", "Primary Peritoneal Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Serous Epithelial Ovarian Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "DSP-7888 Dosing Emulsion", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2017-12-14", "completion_date": "2022-11-29", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311334" }, { "nct_id": "NCT01075464", "title": "A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "MEGF0444A", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2010-02", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01075464" }, { "nct_id": "NCT03452332", "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cervical Adenocarcinoma", "Advanced Vaginal Carcinoma", "Advanced Vulvar Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Metastatic Cervical Adenocarcinoma", "Metastatic Cervical Carcinoma", "Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Metastatic Vaginal Adenocarcinoma", "Metastatic Vaginal Carcinoma", "Metastatic Vulvar Carcinoma", "Recurrent Cervical Adenocarcinoma", "Recurrent Cervical Carcinoma", "Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Vaginal Cancer AJCC v8", "Stage III Vulvar Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Vulvar Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Vulvar Cancer AJCC v8", "Stage IIIC Vulvar Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Adenocarcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2018-07-18", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452332" }, { "nct_id": "NCT03423264", "title": "PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Cancer", "HPV-Related Squamous Cell Carcinoma" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-01-22", "completion_date": "2022-11-08", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03423264" }, { "nct_id": "NCT04090567", "title": "Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Germline BRCA1 Gene Mutation", "Germline BRCA2 Gene Mutation", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2020-07-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04090567" }, { "nct_id": "NCT01281592", "title": "A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumours" ], "interventions": [ { "name": "LOR-253 HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptose Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2011-01", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281592" }, { "nct_id": "NCT00171587", "title": "Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Tumors", "Neoplasm Metastasis" ], "interventions": [ { "name": "PTK787/ZK 222584 (vatalanib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2002-05", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2009-11-19", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00171587" }, { "nct_id": "NCT05519293", "title": "Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "H002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RedCloud Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2022-12-15", "completion_date": "2025-02-28", "has_results": false, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-10-26T04:02:50.677Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05519293" } ] }